Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 10/20 | 0.73 |
| ▸ | GPR34 | Q9UPC5 | 5/20 | 0.73 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.57 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.57 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.57 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.57 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.57 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21778318 | 0.94 | P2RY10 (0.72) | P2RY10GPR34LPAR1ENPP2LPAR4 | |
| SCHEMBL23188400 | 0.94 | P2RY10 (0.72) | P2RY10GPR34LPAR1ENPP2LPAR4 | |
| SCHEMBL14669247 | 0.92 | P2RY10 (0.71) | P2RY10GPR34LPAR1ENPP2LPAR4 | |
| SCHEMBL4804427 | 0.92 | P2RY10 (0.70) | P2RY10GPR34LPAR1 | |
| SCHEMBL14240582 | 0.91 | P2RY10 (0.72) | P2RY10GPR34LPAR1GPR174 | |
| SCHEMBL23188432 | 0.90 | P2RY10 (0.68) | P2RY10GPR34LPAR1ENPP2LPAR4 | |
| SCHEMBL14669245 | 0.90 | P2RY10 (0.68) | P2RY10GPR34LPAR1ENPP2LPAR4 | |
| SCHEMBL21778295 | 0.90 | P2RY10 (0.67) | P2RY10GPR34LPAR1ENPP2LPAR4 | |
| SCHEMBL12075311 | 0.89 | LPAR3 (0.68) | P2RY10GPR34LPAR1ENPP2LPAR4 | |
| SCHEMBL23188413 | 0.89 | P2RY10 (0.67) | P2RY10GPR34LPAR1ENPP2LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210108198-A1 | APPLICATION OF COMPOUND OR TRADITIONAL CHINESE MEDICINE EXTRACT IN PREPARATION OF NUCLEIC ACID DELIVERY AGENT AND RELATED PRODUCTS THEREOF | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2021-04-15 | — | — | US | disclosed |
| EP-2718261-B1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORP (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20130026051-A1 | BIOSENSOR | UNIVERSITY OF LEEDS (GB) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210108198-A1 | APPLICATION OF COMPOUND OR TRADITIONAL CHINESE MEDICINE EXTRACT IN PREPARATION OF NUCLEIC ACID DELIVERY AGENT AND RELATED PRODUCTS THEREOF | TRDMT1, HNRNPAB, HNRNPA1 | P2RY10 4517/4885GPR34 3580/4885LPAR1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.